Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their target price on shares of Evogene from $30.00 to $12.00 and set a buy rating on the stock in a research report on Friday, August 23rd.

Evogene Trading Down 4.1 %

Shares of NASDAQ:EVGN opened at $2.84 on Tuesday. The firm has a 50 day simple moving average of $3.50 and a 200-day simple moving average of $5.67. Evogene has a twelve month low of $2.29 and a twelve month high of $10.40. The company has a market capitalization of $117.05 million, a PE ratio of -6.17 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The company had revenue of $0.91 million during the quarter.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its holdings in Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities and Exchange Commission. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.